Validation of a Liquid Chromatography/Tandem Mass Spectrometry Assay for the Quantification of Plasma Dihydroartemisinin

Dona Arlinda, Intan Sari Oktoberia, Muhammad Karyana

Abstract


Background: Insufficient plasma level of dihydroartemisinin (DHA) can select resistance and will further hinder malaria elimination program. We investigated clinical applicability of a validated liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay to quantify plasma concentration of DHA in healthy subjects from a single oral administration of fixed dose combination of Dihydroartemisinin-Piperaquine.

Materials and Methods: Micro-elution solid-phase extraction in a 96-well plate format was used to prepare the samples. DHA separation happened in Acquity UPLCTM BEH C18 column (50 × 2.1 mm, 1.7 µm). Mobile phase was a mixture of acetonitrile-ammonium acetate 10 mM pH 3.5 (50:50, v/v) at 0.3 mL/minute flow rate. Waters Acquity UPLC™ H-Class system coupled with triple quadruple mass spectrometry in positive electrospray ionization mode was used for detection. The internal standard was a stable isotope labelled DHA.

Results: Calibration curve was linear with a correlation coefficient >0.995 over a concentration range of 1–1,000 ng/mL. Bias and variation for accuracy and precision were in the range of 15% (20% at the lower limit of quantification). Using 5 µL sample, lower limit of quantification was 1 ng. Matrix effect was less than 15%. The method was successfully applied to investigate the pharmacokinetics of DHA from five healthy subjects, although carry over and the role of anticoagulants were not tested.

Conclusion: The LC-MS/MS assay for the quantification of plasma DHA was validated for selectivity, linearity, lower limit of quantitation, accuracy, precision, matrix effect and stability. Although clinical applicability was demonstrated, this method was to be improved to address the not-tested validation parameters.

Keywords: dihydroartemisinin, liquid chromatography/tandem mass spectrometry assay (LC-MS/MS), malaria, Indonesia

 


Full Text:

PDF

References


World Health Organization (WHO). World Malaria Report 2018. Geneva: World Health Organization; 2018, article.

Balint GA. Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther. 2001; 90(2–3): 261-5, CrossRef.

Parapini S, Olliaro P, Navaratnam V, Taramelli D, Basilico N. Stability of the antimalarial drug dihydroartemisinin under physiologically relevant conditions: implications for clinical treatment and pharmacokinetic and in vitro assays. Antimicrob Agents Chemother. 2015; 59(7): 4046-52, CrossRef.

Ali S, Jafery N, Farhat K, Waheed A. Analysis of Artemether and Dihydroartemisinin by high performance high liquid chromatography in biological fluids-issues and solutions. Pak J Pharm Sci. 2017; 30(4): 1395-401, article.

Karbwang J, Na-Bangchang K, Molunto P, Banmairuroi V, Congpuong K. Determination of artemether and its major metabolite, dihydroartemisinin, in plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B. 1997; 690(1-2): 259-65, CrossRef.

Navaratnam V, Mordi MN, Mansor SM. Simultaneous determination of artesunic acid and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. J Chromatogr B. 1997; 692(1): 157-62, CrossRef.

Souppart C, Gauducheau N, Sandrenan N, Richard F. Development and validation of a high-performance liquid chromatography–mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. J Chromatogr B. 2002; 774(2): 195-203, CrossRef.

Sabarinath S, Rajanikanth M, Madhusudanan KP, Gupta RC. A sensitive and selective liquid chromatographic/ electrospray ionization tandem mass spectrometric assay for the simultaneous quantification of a-,b-arteether and its metabolite dihydroartemisinin in plasma, useful for pharmacokinetic studies. J Mass Spectrom. 2003; 38: 732-42, CrossRef.

Naik H, Murry DJ, Kirsch LE, Fleckenstein L. Development and validation of a high-performance liquid chromatography–mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma. J Chromatogr B. 2005; 816(233-42): 233-42, CrossRef.

Peys E, Vandenkerckhove J, Hemel JV, Sas B. Simultaneous determination of b-artemether and its metabolite dihydroartemisininin human plasma and urine by a high-performance liquid chromatography-mass spectrometry assay using electrospray ionisation. Chromatographia. 2005; 61: 637-41, CrossRef.

Shi B, Yu Y, Li Z, Zhang L, Zhong Y, Su S, et al. Quantitative analysis of artemether and its metabolite dihydroartemisinin in human plasma by LC with tandem mass spectrometry. Chromatographia. 2006; 64: 523-30, article.

Lai CS, Naira NK, Mansor SM, Olliaro PL, Navaratnam V. An analytical method with a single extraction procedure and two separate high performance liquid chromatographic systems for the determination of artesunate, dihydroartemisinin and mefloquine in human plasma for application in clinical pharmacological studies of the drug combination. J Chromatogr B. 2007; 857(2): 308-14, CrossRef.

Gu Y, Li Q, Melendez V, Weina P. Comparison of HPLC with electrochemical detection and LC–MS/MS for the separation and validation of artesunate and dihydroartemisinin in animal and human plasma. J Chromatogr B. 2008; 867(2): 213-18, CrossRef.

Sitohang V, Sariwati E, Fajariyani SB, Hwang D, Kurnia B, Hapsari RK, et al. Malaria elimination in Indonesia: halfway there. Lancet Glob Health. 2018; 6(6): e604-e6, CrossRef.

Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Eng J Med. 2016; 374(25): 2453-64, CrossRef.

Hanpithakpong W, Kamanikom B, Dondorp A, Singhasivanon P, White N, Day N, et al. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and itsmetabolite dihydroartemisinin in human plasma. J Chromatogr B. 2008; 876(1): 61-8, CrossRef.

EMA. Guideline on Bioanalytical Method Validation. London: European Medicines Agency; 2011, article.

Briggs RJ, Nicholson R, Vazvaei F, Busch J, Mabuchi M, Mahesh KS, et al. Method transfer, partial validation, and cross validation: recommendations for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J. 2014; 16(6): 1143-8, CrossRef.

Lindegardh N, Hanpithakpong W, Kamanikom B, Singhasivanon P, Socheat D, Yi P, et al. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J Chromatogr B. 2008; 876(1): 54-60, CrossRef.

MAC MOD Analytical. Comparison Guide to C18 Reversed Phase HPLC Columns: Comparison Data on Commonly used C18 Phases. Pennsylvania: MAC MOD; 2008, article.

Hanboonkunupakarn B, van der Pluijm RW, Hoglund R, Pukrittayakamee S, Winterberg M, Mukaka M, et al. Sequential open label study of the safety, tolerability and pharmacokinetic interactions between dihydroartemisinin-piperaquin and mefloquine in healthy Thai adults. Antimicrob Agents Chemother. 2019; 63: e00060-19, CrossRef.

Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014; 58(12): 7340-6, CrossRef.

Chinh NT, Quang NN, Thanh NX, Dai B, Geue JP, Addison RS, et al. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob Agents Chemother. 2009; 53(2): 828-31, CrossRef.




DOI: https://doi.org/10.21705/mcbs.v5i3.194

Indexed by:

                     

                    

            


Cell and BioPharmaceutical Institute